AXNX News and Press, Axonics Modulation Technologies Inc. From 11/04/20

Axonics Modulation Technologies, Inc. (AXNX) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants David Lew...

Gainers: [[ALTM]] +54.6%. [[UPWK]] +24.6%. [[QCOM]] +13.2%. [[APHA]] +10.1%. [[MTW]] +9.5%.Losers: [[BLUE]] -13.9%. [[ELF]] -9.4%. [[INGN]] -8.9%. [[AXNX]] -8.7%. [[PING]] -8.7%. For further details see: ALTM, UPWK, AXNX and INGN among after-hours movers

Axonics Modulation Technologies (AXNX): Q3 GAAP EPS of -$0.24 beats by $0.31.Revenue of $35.2M (+2587.0% Y/Y) beats by $12.25M.Shares -6.8%.Press Release For further details see: Axonics Modulation Technologies EPS beats by $0.31, beats on revenue

Axonics generated net revenue of $35.2 million in the third quarter ended September 30, 2020 Over 5,500 patients have been implanted with the Axonics r-SNM System since U.S. commercial launch Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical tec...

Axonics Modulation Technologies (AXNX) submits a supplemental premarket approval ((PMA)) to the FDA, detachable extremity coil magnetic resonance imaging ((MRI)) conditional labeling for 1.5T and 3.0T MR scanners.The FDA previously approved 1.5T and 3.0T MRI conditional labeling with hea...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to ...

ARTISTRY will enroll up to 300 patients across 30 centers in North America and include patients across all four clinical indications for Axonics Therapy Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializi...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report third quarter 2020 financial results and pr...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has be...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previous...